Gala Vega

First-in-human study of JNJ-79635322 (JNJ-5322), a novel, next-generation trispecific antibody (TsAb), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial phase 1 results.

Niels W.C.J. van de Donk, Gala Vega, Aurore Perrot et al. · Journal of Clinical Oncology · 2025 · 25 citations

Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia with <i>KMT2Ar</i> or <i>NPM1</i> Alterations

Christian Récher, Jenny O’Nions, Ibrahim Aldoss et al. · Blood · 2024 · 21 citations · Full text

Cut-Off Values of Hematologic Parameters to Predict the Number of Alpha Genes Deleted in Subjects with Deletional Alpha Thalassemia

Diego Velasco‐Rodríguez, Carlos Blas, Juan Manuel Alonso‐Domínguez et al. · International Journal of Molecular Sciences · 2017 · 20 citations · Full text

Impact of Prior Bendamustine Exposure on Bispecific Antibody Treatment Outcomes for Patients with B-Cell Lymphoma

Gloria Iacoboni, Ángel Serna, Victor Navarro Garcés et al. · Blood · 2023 · 14 citations

CDK9 INHIBITORS: a promising combination partner in the treatment of hematological malignancies

Daniel Morillo, Gala Vega, Víctor Moreno · Oncotarget · 2023 · 13 citations · Full text